ClinicalTrials.gg
CompletedNCT00859521Updated Aug 20, 2024Results posted

Levetiracetam 1000 mg Under Fasting Conditions

A Phase 1 interventional study of Levetiracetam and Keppra® in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-20.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

THe objective of this study is to compare the rate and extent of absorption of an investigational formulation of levetiracetam 1000 mg tablet to an equivalent oral dose of the commercially available reference product under fasting conditions.

Read the detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Healthy Subjects
03

In context

Lead sponsor

Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects must satisfy the following criteria to be considered for study participation:

  • Subject must be male or non-pregnant, non-breast-feeding female
  • Subject must be at least 18 years of age
  • Subject must have a (BMI) between 19 and 30 kg/m2, inclusive, and body weight should be at least 50 kg (110 lbs)
  • Female Subjects - not surgically sterile or at least two years - must agree to utilize one of the following forms of , if sexually active with a male partner, from screening through completion of the study. Approved forms of contraception are abstinence, double barrier (condom with spermicide, diaphragm with spermicide), intra-uterine device (IUD), or vasectomized partner (6 months minimum since vasectomy).
  • Subject must voluntarily consent to participate in this study and provide their written prior to the start of any study-specific procedures.
  • Subject is willing and able to remain in the study unit for the entire duration of each confinement period and return for any outpatient visits.

Exclusion criteria

Exclusion Criteria

Subjects may be excluded for any of the following:

  • History or presence of cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition which, in the opinion of the Investigator would jeopardize the safety of the subject or the validity of the study results.
  • Has a clinically significant abnormal finding on the physical exam, medical history, or clinical laboratory results at screening.
  • History or presence of allergic or adverse response to levetiracetam or related drugs.
  • Has been on a significantly abnormal diet during the four weeks preceding the first dose of study medication.
  • Has donated blood or plasma within 30 days prior to the first dose of study medication.
  • Has participated in another clinical trial within 30 days prior to the first dose of study medication.
  • Has used any over-the-counter (OTC) medication, including nutritional supplements, within 7 days prior to the first dose of study medication.
  • Has used any prescription medication, including hormonal or hormonal replacement therapy, within 14 days prior to the first dose of study medication.
  • Has been treated with any known enzyme altering drugs such as barbiturates, phenothiazines, cimetidine, carbamazepine, etc., within 30 days prior to the first dose of study medication.
  • Has smoked or used tobacco products within 90 days prior to the first dose of study medication.
  • Subject has consumed alcohol, caffeine/xanthine, or grapefruit containing beverages and foods from 48 hours prior to the dose of study medication and throughout the sample collection period.
  • Is a female with a positive pregnancy test result.
  • Female who has used implanted or injected hormonal contraceptives anytime during the 6 months prior to study start.
  • Has an intolerance to venipuncture.
  • Has a positive urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, opiates)
  • Has a history of drug or alcohol abuse.
  • Has had a positive test for, or has been treated for , or .
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Levetiracetam

    Levetiracetam 1000 mg Tablet (test) dosed in first period followed by Keppra® 1000 mg Tablet (reference) dosed in second period

    Drug: Levetiracetam

  • Active comparator
    Keppra®

    Keppra® 1000 mg Tablet (reference) dosed in first period followed by Levetiracetam 1000 mg Tablet (test) dosed in second period

    Drug: Keppra®

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax - Maximum Observed Concentration

    Bioequivalence based on Cmax

    Time frame: Blood samples collected over 36 hour period

  2. AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

    Bioequivalence based on AUC0-inf

    Time frame: Blood samples collected over 36 hour period

  3. AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)

    Bioequivalence based on AUC0-t

    Time frame: Blood samples collected over 36 hour period

07

Results

Posted Aug 25, 2009

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneLevetiracetam (Test) FirstKeppra® (Reference) First
Started1515
Completed1515
Not completed00
Washout
Participant flow — Washout
MilestoneLevetiracetam (Test) FirstKeppra® (Reference) First
Started1515
Completed1514
Not completed01
Withdrew: Withdrawal by subject01
Second Intervention
Participant flow — Second Intervention
MilestoneLevetiracetam (Test) FirstKeppra® (Reference) First
Started1514
Completed1514
Not completed00

Outcome measures

PrimaryCmax - Maximum Observed Concentration

Bioequivalence based on Cmax

Time frame:
Blood samples collected over 36 hour period
Reported as:
Mean · mcg/mL
Cmax - Maximum Observed Concentration
mcg/mLLevetiracetamKeppra®
Cmax - Maximum Observed Concentration30.281 ± 7.75631.512 ± 8.837
Statistical analysis
  • Levetiracetam vs Keppra® · Ratio of geometric means: 96.7 · 90% CI 92.4 to 101Bioequivalence is established when 90% Confidence Interval falls within 80-125.
PrimaryAUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

Bioequivalence based on AUC0-inf

Time frame:
Blood samples collected over 36 hour period
Reported as:
Mean · mcg*h/mL
AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
mcg*h/mLLevetiracetamKeppra®
AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)281.155 ± 49.732285.645 ± 50.480
Statistical analysis
  • Levetiracetam vs Keppra® · Ratio of geometric means: 98.4 · 90% CI 96.9 to 100Bioequivalence is established when 90% Confidence Interval falls within 80-125.
PrimaryAUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)

Bioequivalence based on AUC0-t

Time frame:
Blood samples collected over 36 hour period
Reported as:
Mean · mcg*h/mL
AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
mcg*h/mLLevetiracetamKeppra®
AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)269.172 ± 47.012272.498 ± 48.078
Statistical analysis
  • Levetiracetam vs Keppra® · Ratio of geometric means: 98.8 · 90% CI 97.2 to 100Bioequivalence is established when 90% Confidence Interval falls within 80-125.

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Levetiracetam (Test) FirstKeppra® (Reference) FirstTotal
<=18 years000
Between 18 and 65 years151530
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Levetiracetam (Test) FirstKeppra® (Reference) FirstTotal
Female7411
Male81119
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Levetiracetam (Test) FirstKeppra® (Reference) FirstTotal
White121426
Black202
Asian101
American Indian or Alaska Native011
Region of Enrollment
Region of Enrollment(participants)Levetiracetam (Test) FirstKeppra® (Reference) FirstTotal
United States151530
08

Study locations

1 site
  • CEDRA Clinical Research, LLC
    San Antonio, Texas 78217, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Jan 2007 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2009
First posted
Mar 11, 2009
Start
Jan 2007
Primary completionActual
Jan 2007
CompletionActual
Jan 2007
Results first posted
Aug 25, 2009
Last update
Aug 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00859521
First posted
Mar 11, 2009
Start date
Jan 2007
Primary completion
Jan 2007
Completion
Jan 2007
Results posted
Aug 25, 2009
Last update
Aug 20, 2024

Study contacts

James P Doherty, D.O.
principal investigator · CEDRA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion